Research programme: airway diseases therapeutic - Synovo

Drug Profile

Research programme: airway diseases therapeutic - Synovo

Latest Information Update: 26 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Synovo
  • Class Macrolides
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Chronic obstructive pulmonary disease; Cystic fibrosis

Most Recent Events

  • 26 Jul 2016 Preclinical trials in Chronic obstructive pulmonary disease in Germany (unspecified route)
  • 26 Jul 2016 Preclinical trials in Cystic fibrosis in Germany (unspecified route)
  • 31 Mar 2014 Research programme: airway diseases therapeutic - Synovo receives Orphan Drug status for Cystic fibrosis in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top